& Johnson Johnson is 10% at AQUINOX PHARMACEUTICALS, INC (AQXP). They have made 14 open-market trades across 6 companies since 2014, most recently 2025-11-26.
6 open-market purchases totalling $29.0M since 2014, against 8 sales. Across 6 scored buys the stock is up 15.4% at ninety days, and 12.8 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 50% |
| Avg Move | -9.1% | +5.1% | +15.4% |
| Alpha | -7.0% | +3.5% | +12.8% |
| Scored | 6 | 6 | 6 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 75% | 88% | 88% |
| Avg Move | -19.5% | -8.1% | -10.7% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CVRX | SELL | 2025-11-26 | 2025-12-01 | $10.03 | $64K | -10.6% | -24.6% | -12.7% |
| CVRX | SELL | 2025-11-21 | 2025-11-25 | $10.05 | $27K | -9.6% | -25.6% | -31.9% |
| CVRX | SELL | 2025-11-12 | 2025-11-14 | $10.00 | $10K | +5.4% | -12.4% | -39.0% |
| FUSN | BUY | 2020-06-30 | 2020-07-02 | $17.00 | $12.3M | -1.9% | -20.1% | -27.1% |
| PTGX | BUY | 2016-08-16 | 2016-08-18 | $12.00 | $7.0M | -6.6% | +28.9% | +104.2% |
| AQXP | SELL | 2015-08-10 | 2015-08-12 | $22.41 | $33.9M | -35.3% | -0.6% | -0.6% |
| NVRO | SELL | 2015-06-08 | 2015-06-08 | $47.94 | $48.4M | +0.3% | +0.1% | +0.1% |
| NERV | BUY | 2015-03-18 | 2016-02-12 | $4.93 | $3.0M | +5.7% | +24.3% | +17.8% |
| NERV | BUY | 2015-03-13 | 2015-03-17 | $4.81 | $2.9M | -16.7% | -2.0% | -2.0% |
| AQXP | SELL | 2014-12-16 | 2014-12-18 | $7.62 | $62K | -35.3% | -0.6% | -0.6% |
| AQXP | SELL | 2014-12-11 | 2014-12-15 | $7.51 | $38K | -35.3% | -0.6% | -0.6% |
| AQXP | SELL | 2014-12-08 | 2014-12-10 | $7.72 | $64K | -35.3% | -0.6% | -0.6% |
| NVRO | BUY | 2014-11-12 | 2014-11-12 | $18.00 | $720K | +0.3% | +0.1% | +0.1% |
| AQXP | BUY | 2014-03-12 | 2015-02-03 | $11.00 | $3.0M | -35.3% | -0.6% | -0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| AQXP | 1,383,366 | $5.1M |
| GNCA | 1,388,645 | $71K |
| Total | $3.9B |
Shares reported on the most recent Form 4, priced at the 2025-12-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Scored | 8 | 8 | 8 |